Endologix Announces First Patient Treated in Ventana(TM) U.S. Clinical Trial
Endologix, Inc. (Nasdaq: ELGX) announced today that the first patient has been enrolled in the Company's U.S. clinical trial to evaluate the Ventana™ Fenestrated Stent Graft System for the endovascular repair of juxtarenal and pararenal abdominal aortic aneurysms (AAAs). The procedure was performed by Matthew Eagleton, MD (Cleveland Clinic Foundation, Department of Vascular Surgery). National Principal Investigator Daniel G. Clair, MD (Chairman, Department of Vascular Surgery, Cleveland Clinic Foundation) proctored the procedure.
Dr. Eagleton said, "We are excited to be the first investigational site to enroll a patient in the Ventana trial using this innovative new stent graft technology. This trial will offer participation to patients with abdominal aortic aneurysms that extend near or involve the renal arteries – patients who are not treatable with any of the approved endovascular aneurysm repair devices. The Ventana stent graft is designed with movable fenestrations for in vivo adjustment to match the specific location of a patient's renal arteries along the aorta, which is essential to addressing the anatomical challenges of these aneurysms. The Ventana system performed well and post-procedure imaging showed that the stent graft completely sealed the aneurysm and maintained blood flow to the kidneys."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.